The goal of this project is to describe the properties of malignant and normal stem cells in relation to autologous marrow transplantation by studying the clonal characteristics of defined cell populations using X- linked or tumor-specific markers. this study will identify and follow cases of clonal hematopoiesis while in CR after therapy for acute leukemia which will determine prevalence and better describe the biologic nature of the leukemic stem cell. A determination of outcome in those individuals who proceed to AMT may ultimately improve results of therapy. Studies of N-ras and c-fms mutations will be the initial studies in identifying a marker, for this potentially early phase in the pathogenesis of leukemia. This study will determine the clonal origins of the malignant myeloma clone, utilizing the unique rearrangement sequence of the immunoglobulin heavy chain to analyze cell compartments representative of a differentiation stage defined by the presence or absence of certain cell surface antigens. Finally this study would demonstrate convincingly that clonal reconstitution of hematopoiesis after AMT does occur in humans. Using X-linked markers, serial samples would be analyzed from before and after transplant to detect shifting clonal ratios, indicating a change in contribution from the stem cell pool which would result, statistically, from a decreased stem cell population. The results of this analysis would be correlated with clinical outcome and associations to various kinds of ex vivo marrow manipulation would be sought.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047748-05
Application #
3773355
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bensinger, W I (2009) Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 23:442-8
Bensinger, William (2008) Stem-cell transplantation for multiple myeloma in the era of novel drugs. J Clin Oncol 26:480-92
Bensinger, William I (2007) Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? Best Pract Res Clin Haematol 20:783-95
Bensinger, William I (2007) Reduced intensity allogeneic stem cell transplantation in multiple myeloma. Front Biosci 12:4384-92
Zaucha, Renata E; Buckner, Dean C; Barnett, Todd et al. (2006) Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. Int J Radiat Oncol Biol Phys 64:227-34
Bensinger, W I (2006) The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 20:1683-9
Bensinger, William I (2004) The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Compr Canc Netw 2:371-8
Bensinger, William I (2004) The current status of hematopoietic stem cell transplantation for multiple myeloma. Clin Adv Hematol Oncol 2:46-52
Yusuf, U; Frangoul, H A; Gooley, T A et al. (2004) Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 33:805-14
Einsele, H; Bamberg, M; Budach, W et al. (2003) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Bone Marrow Transplant 32:593-9

Showing the most recent 10 out of 150 publications